

New study reveals AB-Biotics nature-backed probiotic blend for infants significantly improves symptoms of colic

07th September 2021 - New scientific research highlights the beneficial effect of AB-Biotics' AB-KOLICARE® - which contains a 100% natural blend of science-backed probiotics - in infants with colic. Adding to an existing bank of science exploring the role of probiotics in infantile colic, the findings revealed that daily oral supplementation of AB-KOLICARE® significantly improves symptoms of the condition, including crying time - creating opportunities for innovation in the infant nutrition space.

Infant colic, also known as excessive crying syndrome, is a common disorder in 1 - 5-month-old infants, marked by frequent and prolonged crying or fussing in otherwise healthy babies. Its etiology is unclear, but evidence regarding the implications of infant gut microbiota and overall gut health is rising in importance. This latest randomized double-blind controlled study investigated the impact of daily oral administered AB-KOLICARE® - combining patented probiotic strains *Bifidobacterium longum* KABP®-042 (CECT 7894) and *Pediococcus pentosaceus* KABP®-041 (CECT 8330) - on the symptoms of infantile colic. Conducted in 112 exclusively breastfed or mixed fed infants, it found that supplementation with AB-KOLICARE® for 21 days resulted in shorter crying and/or fussing time and less episodes of crying and/or fussing compared to the placebo group. Of note, although both groups showed a response, infants receiving the probiotic solution displayed a clinically significant response in the first week compared to babies in the

control group (83% vs 36%), and despite babies in both groups improving over time, probiotic treatment offered superior results on day 21. In addition, the probiotic formula improved fecal consistency. It was therefore concluded that AB-KOLICARE® is an effective solution for the prevention and treatment of infant colic.

“Colic can be an extremely distressing experience, for both babies and their families,” comments Jordi Riera, Chief Business Development Officer, AB-Biotics. *“Emerging research shows that babies with infant colic have a different microbiota composition than those without. For instance, the presence of Bifidobacterium – beneficial bacteria that digest dietary fiber, help to prevent infection, and produce vitamins – is just 0.3% in colic babies, compared to 10% in non-colic infants. This suggests that gut microbiota may play an important role in the development of the condition and explains why probiotics are being explored as a potential treatment due to their gut-strengthening properties. In this study, the probiotic solution contained a strain of B. longum, which is a Human Resident Bifidobacteria (HRB) and one of the most common Bifidobacteria in healthy infants. This is significant since most other probiotic solutions for infants contain non-HRB such as B. animalis.”*

AB-Biotics' AB-KOLICARE® is a 100% natural and safe probiotic formula of human origin, specially designed for infant gut health. Opposed to some other probiotic products for infants on the market, the strains in AB-KOLICARE® are present in healthy infants, not adults or other mammal sources. AB-KOLICARE® promotes the maturation and balance of intestinal microbiota in babies and stimulates the growth of *Bifidobacterium*, while

reducing pathogens. The oil-based solution is also demonstrated to have anti-inflammatory and anti-bloating properties and is easy to administer and effective regardless of type of feeding (breastfed or formula), gender or weight, making it an attractive option for colic babies.

To learn more about how AB-KOLICARE® is supporting innovation in the infant nutrition market, visit <https://www.ab-biotics.com/products/pediatric-health/>

-----ENDS-----

About AB-BIOTICS

AB-BIOTICS is a Spanish biotech company which is part of the KANEKA Group. AB-BIOTICS focuses on research, development, protection, and distribution of its own solutions, which contribute to improving people's health and wellbeing. It has 2 divisions:

1. Functional Ingredients: probiotics and other nutraceuticals for pharmaceutical and food sectors.
2. Genetics: genetic analyses for conducting pharmacogenetic studies which provide specialists with more information about the most effective therapies and doses for each patient

For press information, please contact: Camille Seoane, Barrett Dixon Bell, Craig Court, 25 Hale Road, Altrincham, Cheshire WA14 2EY, UK. Tel: +44 (0)161 925 4700. E-mail:

camille@bdb.co.uk